Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TDP2 | O95551 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397236 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL15840598 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL19385517 | 0.75 | MAPT (1.00) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL15840824 | 0.75 | STAT3 (0.55) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL22013497 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL31320227 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL28611695 | 0.74 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL22013853 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL28614773 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ARAB9ALMNA | |
| SCHEMBL15840763 | 0.72 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2ARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213978-B2 | Madrasin-derivative compounds, composition and uses thereof for treating cancer | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-02-04 | — | — | US | disclosed |
| EP-3880205-B1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2023-08-30 | — | — | EP | disclosed |
| EP-3880205-B1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | ROUSSY INST GUSTAVE (FR) | 2023-08-30 | — | — | EP | disclosed |
| CN-113226323-A | Madricin derivative compounds, compositions and uses thereof for treating cancer | 法国古士塔柏罗斯学院 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020099650-A1 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12213978-B2 | Madrasin-derivative compounds, composition and uses thereof for treating cancer | PTPRS, PTMS, PTPRC | ALDH1A1 1922/4885MAPT 1578/4885KMT2A 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.